4.3 Article

The Progression of the Stargardt Disease Type 4 (ProgStar-4) Study: Design and Baseline Characteristics (ProgStar-4 Report No. 1)

Journal

OPHTHALMIC RESEARCH
Volume 60, Issue 3, Pages 185-194

Publisher

KARGER
DOI: 10.1159/000491791

Keywords

Stargardt disease type 4; PROM 1; Natural history study; Clinical trials; End points

Categories

Funding

  1. Austrian Science Fund (FWF) [J 3383-B23]
  2. German National Academy of Sciences Leopoldina [LPDS 2015-14]
  3. Shulsky Foundation, New York, NY
  4. Foundation Fighting Blindness Clinical Research Institute (FFB CRI)
  5. National Centre of Competence in Research (NCCR) Molecular Systems Engineering (University of Basel and ETH Zurich)
  6. Swiss National Science Foundation
  7. USB
  8. Acucela Inc.
  9. NightstaRx Ltd.
  10. Ophthotech Corporation
  11. Spark Therapeutics England Ltd.

Ask authors/readers for more resources

Background/Aims: To describe the design and baseline characteristics of patients enrolled in the multicenter, prospective natural history study of Stargardt disease type 4. Methods: Fifteen eligible patients aged 6 years and older at baseline, harboring disease-causing variants in the PROM 1 gene, and with specified ocular lesions were enrolled. They were examined at baseline using a standard protocol, with 6 monthly follow-up visits for a 2-year period including best-corrected ETDRS visual acuity, spectral-domain optical coherence tomography, fundus autofluorescence (FAF), mesopic and scotopic microperimetry (MP). Areas of definitely decreased FAF (DDAF) and questionably decreased FAF were outlined and quantified on FAF images. Results: Amongst the 15 patients (29 eyes) that were enrolled at 5 centers in the USA and Europe, 10 eyes (34.5%) had areas of DDAF with an average lesion area of 3.2 +/- 3.5 mm(2) (range 0.36-10.39 mm(2)) at baseline. The mean retinal sensitivity of the posterior pole derived from mesopic MP was 8.8 +/- 5.8 dB. Conclusions: Data on disease progression in PROM1-related retinopathy from this study will contribute to the characterization of the natural history of disease and the exploration of the utility of several modalities to track progression and therefore to potentially be used in future interventional clinical trials. (C) 2018 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available